Laman UtamaSCNI • NASDAQ
add
Scinai Immunotherapeutics Ltd - ADR
Tutup sebelumnya
$3.48
Julat hari
$3.52 - $3.80
Julat tahun
$2.34 - $8.92
Permodalan pasaran
3.01J USD
Bilangan Purata
10.44K
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | 168.00K | — |
Perbelanjaan pengendalian | 2.17J | 3.28% |
Pendapatan bersih | 10.46J | 236.50% |
Margin untung bersih | 6.22K | — |
Pendapatan bagi setiap syer | — | — |
EBITDA | -1.92J | 1.79% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.03J | -83.78% |
Jumlah aset | 12.26J | -34.02% |
Jumlah liabiliti | 2.26J | -89.39% |
Jumlah ekuiti | 10.00J | — |
Syer tertunggak | 853.00K | — |
Harga kepada buku | 0.30 | — |
Pulangan pada aset | -44.63% | — |
Pulangan pada modal | -48.85% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 10.46J | 236.50% |
Tunai daripada operasi | -2.04J | 8.28% |
Tunai daripada pelaburan | -4.00K | 80.00% |
Tunai daripada pembiayaan | 8.00K | -99.26% |
Perubahan bersih dalam tunai | -1.92J | -67.45% |
Aliran tunai bebas | -2.48J | -53.77% |
Perihal
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
Diasaskan
1 Jan 2003
Tapak web
Pekerja
31
